Association of lipids and lipid-lowering drugs with peripheral arterial disease: A Mendelian randomization study

20245 citationsJournal Articlehybrid Open Access

Authors

Mengjun Tao · First Affiliated Hospital of Wannan Medical College

Yuanxiang Zhang · Wannan Medical College

Qi Li · Nanjing University of Chinese Medicine

Xuebing Feng · Nanjing University of Chinese Medicine

Cheng Ping · First Affiliated Hospital of Wannan Medical College

Abstract

Based on genetic evidence, dyslipidemia is an important risk factor for PAD. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors may be an effective strategy for the treatment of PAD.

Topics & Keywords

Peripheral Artery Disease Management Lipoproteins and Cardiovascular Health Atherosclerosis and Cardiovascular Diseases

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Journal of clinical lipidology

Volume 18, Issue 6, pp. e968-e976

DOI: 10.1016/j.jacl.2024.06.007

Field-Weighted Citation Impact: 2.84